Published in BMC Cancer on August 18, 2015
Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis. PLoS Med (2016) 0.75
Essential medicines for cancer: WHO recommendations and national priorities. Bull World Health Organ (2016) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Planning cancer control in Latin America and the Caribbean. Lancet Oncol (2013) 8.43
Breast cancer as a global health concern. Cancer Epidemiol (2009) 2.71
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J (2006) 1.85
Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol (2011) 1.77
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog (2012) 1.75
Breast cancer in Brazil: present status and future goals. Lancet Oncol (2012) 1.49
Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. Breast (2011) 1.39
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann Oncol (2013) 1.27
Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol (2012) 1.19
Essential medicines are more available than other medicines around the globe. PLoS One (2014) 1.12
Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. Cancer (2008) 1.10
Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer (2008) 1.07
Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. PLoS Med (2014) 0.95
Selection of oncology medicines in low- and middle-income countries. Ann Oncol (2014) 0.93
Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. Eur J Health Econ (2013) 0.92
Breast cancer management in middle-resource countries (MRCs): consensus statement from the Breast Health Global Initiative. Breast (2011) 0.91
Breast health global initiative (BHGI) outline for program development in Latin America. Salud Publica Mex (2009) 0.91
Cancer surgery in low-income countries: an unmet need. Arch Surg (2012) 0.90
Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87
Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer (2008) 0.87
Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 0.84
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal. Health Technol Assess (2009) 0.82
New developments and future directions in systemic therapy. Clin Oncol (R Coll Radiol) (2012) 0.81
The use of paclitaxel in the management of early stage breast cancer. Health Technol Assess (2009) 0.77
Developing nations face challenges as breast cancer rises. J Natl Cancer Inst (2011) 0.77
Study of compliance with prescription information sheet of trastuzumab prescriptions in a tertiary level hospital. Farm Hosp (2011) 0.77
When the price is right. Nat Biotechnol (2006) 0.76